Cargando…

Lipoxin A4 Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis via Promoting the Regression of Inflammation

INTRODUCTION: As a mediator of inflammation resolution, lipoxin A4 (LXA4) mainly plays an anti-inflammatory role and promotes inflammation resolution. LXA4 plays an inhibiting inflammatory role in a variety of diseases, tissues and cells, including keratinocytes. Psoriasis is a chronic inflammatory...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Feng, Qu, Zilu, Chen, Kai, Zhang, Ping, Wang, Bei, Jiang, Ruili, Zuo, Yuyue, Xia, Ping, Chen, Hongxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422962/
https://www.ncbi.nlm.nih.gov/pubmed/37575152
http://dx.doi.org/10.2147/CCID.S418467
_version_ 1785089342143725568
author Hu, Feng
Qu, Zilu
Chen, Kai
Zhang, Ping
Wang, Bei
Jiang, Ruili
Zuo, Yuyue
Xia, Ping
Chen, Hongxiang
author_facet Hu, Feng
Qu, Zilu
Chen, Kai
Zhang, Ping
Wang, Bei
Jiang, Ruili
Zuo, Yuyue
Xia, Ping
Chen, Hongxiang
author_sort Hu, Feng
collection PubMed
description INTRODUCTION: As a mediator of inflammation resolution, lipoxin A4 (LXA4) mainly plays an anti-inflammatory role and promotes inflammation resolution. LXA4 plays an inhibiting inflammatory role in a variety of diseases, tissues and cells, including keratinocytes. Psoriasis is a chronic inflammatory skin disease mediated by dysregulation of inflammation of immune cells and keratinocytes. However, the expression and role of LXA4 in psoriasis-like mouse models are still unclear. METHODS: Imiquimod (IMQ) topical treatment of dorsal skin induces psoriasis-like dermatitis in BALB/c mice, pretreated intraperitoneally with or without LXA4 prior to IMQ application. Severity of dorsal lesions is assessed by using a modified human scoring system and histopathology. The concentration of LXA4 and the expression of ALOX15 (a key gene in LXA4 metabolic synthesis) in lesional skins were detected by ELISA and Western blot. Quantitative PCR and ELISA were conducted to detect the mRNA and secretion levels of inflammatory cytokines. The proportion of IL-17A-producing γδT cells in skin and skin draining cervical lymph nodes and helper (Th) 17 cells in spleens was evaluated by flow cytometry. Western blotting was used to analyze the expressions of p-STAT3 and TRAF6. RESULTS: The concentration of LXA4 and the expression of ALOX15 were decreased in IMQ-induced lesional skin. LXA4 significantly relieved psoriasis-like lesions in IMQ-induced mouse models. Furthermore, LXA4 decreased IMQ-induced systemic inflammation, including reduced the proportion of IL-17A-producing gdT cells in skin and skin draining cervical lymph nodes and Th17 cells in spleens, the secretion and expression of CCL20, IL-17A, IL-1β, and TNF-α in skin and serum. LXA4 markedly inhibited IMQ-induced expression of TRAF6 and p-STAT3. CONCLUSION: LXA4 significantly ameliorates IMQ-induced psoriasis-like inflammation, and LXA4 can be used as a target for psoriasis treatment.
format Online
Article
Text
id pubmed-10422962
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-104229622023-08-13 Lipoxin A4 Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis via Promoting the Regression of Inflammation Hu, Feng Qu, Zilu Chen, Kai Zhang, Ping Wang, Bei Jiang, Ruili Zuo, Yuyue Xia, Ping Chen, Hongxiang Clin Cosmet Investig Dermatol Original Research INTRODUCTION: As a mediator of inflammation resolution, lipoxin A4 (LXA4) mainly plays an anti-inflammatory role and promotes inflammation resolution. LXA4 plays an inhibiting inflammatory role in a variety of diseases, tissues and cells, including keratinocytes. Psoriasis is a chronic inflammatory skin disease mediated by dysregulation of inflammation of immune cells and keratinocytes. However, the expression and role of LXA4 in psoriasis-like mouse models are still unclear. METHODS: Imiquimod (IMQ) topical treatment of dorsal skin induces psoriasis-like dermatitis in BALB/c mice, pretreated intraperitoneally with or without LXA4 prior to IMQ application. Severity of dorsal lesions is assessed by using a modified human scoring system and histopathology. The concentration of LXA4 and the expression of ALOX15 (a key gene in LXA4 metabolic synthesis) in lesional skins were detected by ELISA and Western blot. Quantitative PCR and ELISA were conducted to detect the mRNA and secretion levels of inflammatory cytokines. The proportion of IL-17A-producing γδT cells in skin and skin draining cervical lymph nodes and helper (Th) 17 cells in spleens was evaluated by flow cytometry. Western blotting was used to analyze the expressions of p-STAT3 and TRAF6. RESULTS: The concentration of LXA4 and the expression of ALOX15 were decreased in IMQ-induced lesional skin. LXA4 significantly relieved psoriasis-like lesions in IMQ-induced mouse models. Furthermore, LXA4 decreased IMQ-induced systemic inflammation, including reduced the proportion of IL-17A-producing gdT cells in skin and skin draining cervical lymph nodes and Th17 cells in spleens, the secretion and expression of CCL20, IL-17A, IL-1β, and TNF-α in skin and serum. LXA4 markedly inhibited IMQ-induced expression of TRAF6 and p-STAT3. CONCLUSION: LXA4 significantly ameliorates IMQ-induced psoriasis-like inflammation, and LXA4 can be used as a target for psoriasis treatment. Dove 2023-08-08 /pmc/articles/PMC10422962/ /pubmed/37575152 http://dx.doi.org/10.2147/CCID.S418467 Text en © 2023 Hu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Hu, Feng
Qu, Zilu
Chen, Kai
Zhang, Ping
Wang, Bei
Jiang, Ruili
Zuo, Yuyue
Xia, Ping
Chen, Hongxiang
Lipoxin A4 Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis via Promoting the Regression of Inflammation
title Lipoxin A4 Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis via Promoting the Regression of Inflammation
title_full Lipoxin A4 Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis via Promoting the Regression of Inflammation
title_fullStr Lipoxin A4 Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis via Promoting the Regression of Inflammation
title_full_unstemmed Lipoxin A4 Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis via Promoting the Regression of Inflammation
title_short Lipoxin A4 Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis via Promoting the Regression of Inflammation
title_sort lipoxin a4 ameliorates imiquimod-induced psoriasis-like dermatitis via promoting the regression of inflammation
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422962/
https://www.ncbi.nlm.nih.gov/pubmed/37575152
http://dx.doi.org/10.2147/CCID.S418467
work_keys_str_mv AT hufeng lipoxina4amelioratesimiquimodinducedpsoriasislikedermatitisviapromotingtheregressionofinflammation
AT quzilu lipoxina4amelioratesimiquimodinducedpsoriasislikedermatitisviapromotingtheregressionofinflammation
AT chenkai lipoxina4amelioratesimiquimodinducedpsoriasislikedermatitisviapromotingtheregressionofinflammation
AT zhangping lipoxina4amelioratesimiquimodinducedpsoriasislikedermatitisviapromotingtheregressionofinflammation
AT wangbei lipoxina4amelioratesimiquimodinducedpsoriasislikedermatitisviapromotingtheregressionofinflammation
AT jiangruili lipoxina4amelioratesimiquimodinducedpsoriasislikedermatitisviapromotingtheregressionofinflammation
AT zuoyuyue lipoxina4amelioratesimiquimodinducedpsoriasislikedermatitisviapromotingtheregressionofinflammation
AT xiaping lipoxina4amelioratesimiquimodinducedpsoriasislikedermatitisviapromotingtheregressionofinflammation
AT chenhongxiang lipoxina4amelioratesimiquimodinducedpsoriasislikedermatitisviapromotingtheregressionofinflammation